Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats.

Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ

Endocrinology1 Oct 1989Cited by 63 (Europe PMC)

PMID2791976DOI10.1210/endo-125-4-2022PepBankPUB-02791976

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased trabecular calcium by approximately 19% versus vehicle.
In plain wordsIn rats, PTH increased trabecular calcium versus vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular calcium
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneous · 12 daysAs given in this study (rat).
Source sentences
Summary
After 12 days, PTH, at 8 micrograms/100 g, increased trabecular Ca, dry weight, and hydroxyproline by approximately 19%, 36%, and 53%, respectively, while the bone mass of PTHrP-treated rats was comparable to vehicle-treated rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197601
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased trabecular dry weight by approximately 36% versus vehicle.
In plain wordsIn rats, PTH increased trabecular dry weight versus vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular dry weight
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneous · 12 daysAs given in this study (rat).
Source sentences
Summary
After 12 days, PTH, at 8 micrograms/100 g, increased trabecular Ca, dry weight, and hydroxyproline by approximately 19%, 36%, and 53%, respectively, while the bone mass of PTHrP-treated rats was comparable to vehicle-treated rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197602
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased trabecular hydroxyproline by approximately 53% versus vehicle.
In plain wordsIn rats, PTH increased trabecular hydroxyproline versus vehicle.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular hydroxyproline
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneous · 12 daysAs given in this study (rat).
Source sentences
Summary
After 12 days, PTH, at 8 micrograms/100 g, increased trabecular Ca, dry weight, and hydroxyproline by approximately 19%, 36%, and 53%, respectively, while the bone mass of PTHrP-treated rats was comparable to vehicle-treated rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197603
04AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased trabecular bone mass by 43-48%, compared with 30-37% with PTHrP.
In plain wordsIn rats, PTH increased trabecular bone mass more than PTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone mass after 12 days
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
PTHrP 32 micrograms/100 g
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneous · 12 daysAs given in this study (rat).
Source sentences
Summary
PTHrP at a higher dose of 32 micrograms/100 g, increased trabecular bone mass by 30-37%, compared to the 43-48% increase induced by PTH at 8 micrograms/100 g after 12 days.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197604
05AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased trabecular bone mass by 43-61%, compared with 24-36% with PTHrP.
In plain wordsIn rats, PTH increased trabecular bone mass more than PTHrP.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone mass after 26 days
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
PTHrP 16 micrograms/100 g
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneous · 26 daysAs given in this study (rat).
Source sentences
Summary
When treatment was extended to 26 days, PTHrP, at 16 micrograms/100 g, increased trabecular bone mass by 24-36%, respectively, compared to the 43-61% increase induced by PTH at 8 micrograms/100 g.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197605
06AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased cortical bone mass by 15-25%.
In plain wordsIn rats, PTH increased cortical bone mass.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone mass
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Unlike PTH, which increased cortical bone mass by 15-25%, PTHrP increased cortical bone mass only at the highest dose tested, 32 micrograms/100 g.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197606
07AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH increased bone forming surfaces versus controls.
In plain wordsIn rats, PTH increased bone forming surfaces versus controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone forming surfaces
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Bone forming surfaces but not bone apposition rate were increased by PTH and PTHrP while resorption measures remained comparable to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197607
08AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH did not increase bone apposition rate versus controls.
In plain wordsIn rats, PTH did not increase bone apposition rate versus controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone apposition rate
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Bone forming surfaces but not bone apposition rate were increased by PTH and PTHrP while resorption measures remained comparable to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197608
09AnimalAnimal study (in vivo)Efficacy outcome
In rats, bone resorption measures with PTH remained comparable to control values.
In plain wordsIn rats, bone resorption with PTH was similar to controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone resorption measures
Study
ratn: not reported in source
young male Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Bone forming surfaces but not bone apposition rate were increased by PTH and PTHrP while resorption measures remained comparable to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197609
10AnimalAnimal study (in vivo)Safety outcome
In rats, serum calcium remained within the physiological range in all groups, including PTH-treated rats.
In plain wordsIn rats, serum calcium stayed within the physiological range in all groups, including PTH-treated rats.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerum calcium
Study
ratn: not reported in source
young male Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Although serum Ca and Pi remained in the physiological range for all rats, the values for PTHrP-treated rats were consistently higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197610
11AnimalAnimal study (in vivo)Safety outcome
In rats, serum inorganic phosphate remained within the physiological range in all groups, including PTH-treated rats.
In plain wordsIn rats, serum phosphate stayed within the physiological range in all groups, including PTH-treated rats.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerum inorganic phosphate
Study
ratn: not reported in source
young male Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
8 micrograms/100 g daily · subcutaneousAs given in this study (rat).
Source sentences
Summary
Although serum Ca and Pi remained in the physiological range for all rats, the values for PTHrP-treated rats were consistently higher.
1 context sentence(design, population, supporting numbers)
Summary · context
Dose response experiments were done on young, male Sprague-Dawley rats given sc vehicle, human (h) PTH (1-34) at 8 micrograms/100 g or PTHrP (1-34) at 1-32 micrograms/100 g daily for 12 days or 26 days.
Report a problemFND-0279197611

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.